[{"Assets_0_FY_USD":166999000.0,"CommonStockSharesOutstanding_0_FY_shares":269363696.0,"EarningsPerShareBasic_1_FY_USD":-0.1,"EarningsPerShareBasic_4_FY_USD":-0.41,"EarningsPerShareDiluted_1_FY_USD":-0.1,"EarningsPerShareDiluted_4_FY_USD":-0.41,"NetIncomeLoss_1_FY_USD":-27453000.0,"NetIncomeLoss_4_FY_USD":-86350000.0,"StockholdersEquity_0_FY_USD":-9058000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_4_FY_shares":211874000.0,"WeightedAverageNumberOfSharesOutstandingBasic_4_FY_shares":211874000.0,"Ticker":"AMRN","CIK":"897448","name":"AMARIN CORP PLCUK","OfficialName":"Amarin Corporation plc","form":"10-K","period":"20161231","fy":"2016.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1265593617.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170301"}]